Literature DB >> 11999622

The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin.

Carol A Westall1, William J Logan, Kim Smith, J Raymond Buncic, Carole M Panton, Mohamed Abdolell.   

Abstract

The purpose of this longitudinal study was to identify changes in ERG responses associated with vigabatrin treatment. We accomplished this by recording longitudinally ERGs in children before and during vigabatrin treatment and comparing results between children on vigabatrin monotherapy and those taking additional anticonvulsive medications. Thirty-three children on vigabatrin therapy were tested; the duration between visits was approximately 6 months. Thirteen children were assessed initially before starting vigabatrin therapy and seven were assessed soon after (age range 1.5-126 months, median 6 months). The remaining 13 patients were already on vigabatrin at the time of initial visit (age range 6.5-180 months, median 16 months). ERGs were tested using the standard protocol established by the International Society for Clinical Electrophysiology of Vision, with Burian-Allen bipolar contact-lens electrodes. In addition to standard responses we recorded photopic oscillatory potentials (OPs). All 33 patients were tested longitudinally on at least two occasions and 11 were tested on three occasions. For children whose only anticonvulsive drug was vigabatrin there was a significant curvature (quadratic function, p < 0.05) of the predicted cone b-wave amplitude with time; exhibited as increase in b-wave amplitude followed by subsequent decrease. Descriptive data demonstrated the same pattern in the group taking anticonvulsive medications in addition to vigabatrin. In most children the flicker amplitude declined between 6 months and 1 year of vigabatrin treatment. Our data demonstrated that rod responses, which may be abnormal before initiation of vigabatrin, did not change substantially with vigabatrin treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999622      PMCID: PMC3880358          DOI: 10.1023/a:1014656626174

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  29 in total

1.  GABA, picrotoxin and retinal sensitivity.

Authors:  G W De Vries; A H Friedman
Journal:  Brain Res       Date:  1978-06-16       Impact factor: 3.252

2.  GABA-mediated control of transient signals in the inner retina.

Authors:  R D Mooney
Journal:  Brain Res       Date:  1978-04-21       Impact factor: 3.252

3.  Visual function loss from vigabatrin: effect of stopping the drug.

Authors:  M A Johnson; G L Krauss; N R Miller; M Medura; S R Paul
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

4.  Visual impairment in children with epilepsy treated with vigabatrin.

Authors:  V Gross-Tsur; E Banin; E Shahar; R S Shalev; E Lahat
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

5.  Which ocular and neurologic conditions cause disparate results in visual acuity scores recorded with visually evoked potential and teller acuity cards?

Authors:  C A Westall; J R Ainsworth; J R Buncic
Journal:  J AAPOS       Date:  2000-10       Impact factor: 1.220

6.  Possible role of amacrine cells in the generation of the mammalian ERG b-wave.

Authors:  I Gottlob; L Wündsch; R Pflug
Journal:  Doc Ophthalmol       Date:  1985-10-30       Impact factor: 2.379

7.  Vigabatrin treatment in children.

Authors:  A Fois; S Buoni; R M Di Bartolo; V Di Marco; R Mostardini
Journal:  Childs Nerv Syst       Date:  1994-05       Impact factor: 1.475

8.  Vigabatrin in pediatric epilepsy--an open study.

Authors:  P Uldall; J Alving; L Gram; S Beck
Journal:  J Child Neurol       Date:  1991       Impact factor: 1.987

9.  Optic nerve hypoplasia in association with brain anomalies and an abnormal electroretinogram.

Authors:  G W Cibis; K M Fitzgerald
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

10.  Electroretinography: application to clinical studies of infants.

Authors:  A B Fulton; R M Hansen
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1985 Nov-Dec       Impact factor: 1.402

View more
  19 in total

1.  The effect of GABA and the GABA-uptake-blocker NO-711 on the b-wave of the ERG and the responses of horizontal cells to light.

Authors:  Renate Hanitzsch; Lea Küppers; Andreas Flade
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09       Impact factor: 3.117

2.  A new generation of anticonvulsants for the treatment of epilepsy in children.

Authors:  O Carter Snead; Elizabeth J Donner
Journal:  Paediatr Child Health       Date:  2007-11       Impact factor: 2.253

3.  Electroretinographic (ERG) responses in pediatric patients using vigabatrin.

Authors:  Anne Moskowitz; Ronald M Hansen; Susan E Eklund; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2012-03-20       Impact factor: 2.379

Review 4.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

5.  Vigabatrin can enhance electroretinographic responses in pigmented and albino rats.

Authors:  James D Akula; Emily R Noonan; Alessia Di Nardo; Tara L Favazza; Nan Zhang; Mustafa Sahin; Ronald M Hansen; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2015-03-12       Impact factor: 2.379

6.  Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.

Authors:  Sivan Durbin; Giuseppe Mirabella; J Raymond Buncic; Carol A Westall
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-11       Impact factor: 4.799

7.  Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children.

Authors:  J Raymond Buncic; Carol A Westall; Carole M Panton; J Robert Munn; Leslie D MacKeen; William J Logan
Journal:  Ophthalmology       Date:  2004-10       Impact factor: 12.079

8.  Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina.

Authors:  Qing-Ping Wang; Firas Jammoul; Agnès Duboc; Jie Gong; Manuel Simonutti; Elisabeth Dubus; Cheryl M Craft; Wen Ye; José A Sahel; Serge Picaud
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

9.  Changes in the ERG d-wave with vigabatrin treatment in a pediatric cohort.

Authors:  Rachel Dragas; Carol Westall; Tom Wright
Journal:  Doc Ophthalmol       Date:  2014-07-10       Impact factor: 2.379

10.  Changes in the electroretinogram resulting from discontinuation of vigabatrin in children.

Authors:  Carol A Westall; Rita Nobile; Sharon Morong; J Raymond Buncic; William J Logan; Carole M Panton
Journal:  Doc Ophthalmol       Date:  2003-11       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.